ImmuPharma plc (LON:IMM – Get Free Report) traded up 9.3% during mid-day trading on Saturday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.94 ($0.05). 31,560,066 shares traded hands during trading, an increase of 60% from the average session volume of 19,683,289 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Stock Up 9.3 %
The company’s 50-day moving average is GBX 1.75 and its 200 day moving average is GBX 1.73. The company has a market cap of £16.39 million, a price-to-earnings ratio of -393.60 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- How to Buy Cheap Stocks Step by Step
- MP Materials: Rare Earth Elements Powering the EV Boom
- What Are Some of the Best Large-Cap Stocks to Buy?
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- Investing In Automotive Stocks
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
